BioSpace News Archive

Today, Halo Health announces that Steve Smerz has joined the Company as its new Chief Technology Officer.

Vizgen, a life sciences company developing the next generation of in situ single-cell genomics, today announced the launch of its Pharma Accelerator Lab in response to high demand from leading pharmaceutical companies who are increasingly turning to single-cell and spatial transcriptomics solutions to accelerate their drug development pipelines.

Ribometrix, Inc., today announced a strategic collaboration with Genentech, a member of the Roche Group, to discover and develop novel RNA-targeted small molecule therapeutics against several targets.

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:40 a.m. ET.

AstraZeneca’s FARXIGA (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney disease (CKD) in adults with and without type 2 diabetes (T2D).

CVS Health is now administering COVID-19 vaccines in skilled nursing facilities in 49 states, with the rollout beginning in 36 states and Washington, D.C. last week.

Creative Medical Technology Holdings, Inc. (OTC: CELZ) commented today on a peer-reviewed publication from the University of Miami demonstrating that the intravenous administration of umbilical cord derived stem cells, termed “JadiCells” results in a significant survival improvement in COVID-19 patients.

AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will be participating in the virtual H.C. Wainwright BioConnect 2021 Conference.

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces that members of the management team will be participating in the H.C. Wainwright BioConnect Conference,

Orca Bio, a clinical-stage biotechnology company developing high-precision cell therapies for patients with blood diseases, today announced that Ivan Dimov, Ph.D., Chief Executive Officer, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference.